Fresenius SE & Co. Q1 2025 Earnings Report

Fresenius SE & Co. EPS Results

• Actual EPS: $0.23
• Consensus EPS: $0.22
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: N/A

Fresenius SE & Co. Revenue Results

• Actual Revenue: $5.92 billion
• Expected Revenue: $5.41 billion
• Beat/Miss: Beat by +$513.12 million
• YoY Revenue Growth: N/A

Fresenius SE & Co. Announcement Details

• Quarter: Q1 2025
• Date: 5/7/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation.

Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.